Tag: CTP

  • Zeller to Retire from Center for Tobacco Products in April

    Zeller to Retire from Center for Tobacco Products in April

    Mitch Zeller, the director of the Food and Drug Administration’s Center for Tobacco Products, plans to retire in April 2022 after serving in the post since 2013, reports The Washington Post. In a letter to staff, acting FDA Commissioner Janet Woodcock praised his work as “invaluable and instrumental” to advancing “numerous historic public health milestones in tobacco regulation.”

    A graduate of Dartmouth College and the American University Washington College of Law, Zeller has been working on FDA issues for more than 30 years. He began his career as a public interest attorney in 1982 at the Center for Science in the Public Interest (CSPI). In 1988, Zeller left CSPI to become counsel to the human resources and intergovernmental relations subcommittee of the House of Representatives’ government operations committee, where he conducted oversight of enforcement of federal health and safety laws.

    In 1993, Zeller joined the staff of then FDA Commissioner David Kessler. What began as a two-week assignment by Kessler to examine the practices of the tobacco industry led to his serving as associate commissioner and director of the FDA’s first Office of Tobacco Programs. Instrumental in crafting the agency’s 1996 tobacco regulations, Zeller also represented the FDA before Congress, federal and state agencies. Zeller also served as an official U.S. delegate to the World Health Organization working group for the Framework Convention on Tobacco Control.

    In 2000, Zeller became executive vice president of the American Legacy Foundation. His responsibilities there included marketing, communications, strategic partnerships and, in 2002, creating the foundation’s first Office of Policy and Government Relations. That year, Zeller joined PinneyAssociates, where, as senior vice president, he provided strategic planning and communications advice. 

    He left PinneyAssociates in 2013 to begin his second stint at the FDA.

  • FDA: Synthetic Nicotine May be Considered a Component

    FDA: Synthetic Nicotine May be Considered a Component

    Synthetic nicotine could be considered a component of e-cigarettes, which would allow for the product to be regulated by the U.S. Food and Drug Administration. Mitch Zeller, director of the FDA’s Center for Tobacco Products, said the agency was concerned about the use of synthetic nicotine to avoid regulation and enforcement and is considering its options in dealing with its use.

    Mitch Zeller
    Mitch Zeller, director of the FDA’s Center for Tobacco
    Products

    On Nov. 17, the first day of TMA’s “From Chance to Change” webinar, Zeller said that the agency is charged with regulating tobacco products, which according to the Tobacco Control Act is anything that’s “made or derived from tobacco that is intended for human consumption, including any component, part or accessory of a tobacco product.” Zeller said that components and parts could include everything from coils and batteries to all the ingredients comprised in producing e-liquids (such as flavorings and vegetable glycerin) even if the product does not contain nicotine.

    “That’s an assessment that we need to make on a case-by-case basis based upon the totality of all the information that we have,” said Zeller, adding that another challenge is that synthetic nicotine is now of such high quality and complexity that it has become difficult to differentiate it from nicotine derived from natural tobacco. “Historically, that hasn’t been a problem,” he said. “It’s not a problem now, but it could become a challenge for us going forward.”

    Zeller explained that nicotine is comprised of two isomers: R and S. Tobacco-derived nicotine is 99 percent S, and early synthetic nicotine had a 50-50 split between R isomers and S isomers. However, newer versions of synthetic nicotine have much higher proportions of S isomers (as high as 99.9 percent pure), making it harder to tell synthetic apart from natural nicotine. Tobacco-derived nicotine is also becoming higher in quality.

    “Tobacco-derived nicotine is now being made available at a higher quality … pharmaceutical grade from a purity standpoint. And with that, it may be harder for us to see that chemical fingerprint, if you will, whether it’s tobacco DNA or tobacco-specific nitrosamines,” he said. “We could see this as a problem going forward. Coupled with the clear intent of certain companies to do this to evade FDA regulation … We are concerned about what this means for product regulation, for the public health, and a product like Puff Bar proudly proclaiming its use of synthetic nicotine, [and] being the number-one brand used by youth.”

    In the short term, Zeller said the FDA is talking internally about how to best address the growing number of products that are using synthetic nicotine to skirt FDA regulation. He said the agency is also responding to questions from Congress about synthetic nicotine and providing technical assistance to members when asked.

    “There are a lot of companies out there that pride themselves on playing by the rules. They have every right to expect that the playing field is going to be level. That’s where we come in with our compliance and enforcement authorities,” Zeller said. “We agree that one of the most important things that we can do, using our compliance and enforcement tools, is to level the playing field and to have our actions [in the e-cigarette space], hopefully, serve as a deterrent. There’s nothing that I can say from a compliance enforcement standpoint on synthetic nicotine other than we have ongoing investigations.”

    For more on Zeller’s speech at TMA read the next issue of Vapor Voice coming in mid-December.

  • FDA: 102 Warnings for Illegal E-liquid Sales so Far in 2021

    FDA: 102 Warnings for Illegal E-liquid Sales so Far in 2021

    It is now at 102 in 2021. Posting on its website on April 30 that it has issued six more warning letters to companies for marketing illegal e-liquids, the U.S. Food and Drug Administration (FDA) continues its blitz to pull any vaping products from the U.S. market that haven’t submitted a premarket tobacco product application (PMTA) to the FDA’s Center for Tobacco Products.

    Credit: Yuri Hoyda

    Unfortunately, the FDA often only lists a product or two that a company is selling as illegal. It then states that there may be more, but it is impossible to know if the warnings encompass all the company’s registered products. The companies receiving the letters on April 9, the products they were cited for and the number of products each has registered with the FDA include:

    • Smoking Fire Vapor: e-liquid products without a marketing authorization order including: Smokin’ Fire Vapor Captain Custard and Smokin’ Fire Vapor Wrecking Ball; registered manufacturer with over 180 products listed with FDA.
    • Simply E-Juice: e-liquid without a marketing authorization order including: Simply Bodacious Blueberry and Simply Glorious Grape; registered manufacturer with over 200 products listed with FDA.
    • Smokecignals: e-liquid products without a marketing authorization order including: Blue Puppet and Black Frost; registered manufacturer with over 100 products listed with FDA.
    • Rocky Top Vapor: e-liquid products without a marketing authorization order including: RTV LTD Berry Shake and RTV LTD Pink Lemonade;  registered manufacturer with over 470 products listed with FDA.
    • VaporBombCOM: e-liquid products without a marketing authorization order including VaporBomb.com: Cafe Mocha and Cinnamon Danish Swirl; a registered manufacturer with over 2,200 listed with FDA.
    • B-X Vapor: e-liquid products without a marketing authorization order including: B-X Vapor Dad’s Milk and B-X Vapor Watermelon Crack; registered manufacturer with over 1,100 products listed with FDA.

    The regulatory agency has now issued warning letters to 102 companies in 2021 for violating PMTA rules. Companies that receive warning letters from the FDA have to submit a written response to the letter within 15 working days from the date of receipt describing the company’s corrective actions, including the dates on which it discontinued the violative sale, and/or distribution of the products. They also require the company’s plan for maintaining compliance with the FD&C Act in the future.

    In February, the director of the FDA’s Center for Tobacco Products, Mitch Zeller, said that there were over 400 million vaping-related products that required a PMTA in order to remain on the market. “These warning letters are the result of continued surveillance and internet monitoring for violations of tobacco laws and regulations. We want to make clear to all tobacco product manufacturers and retailers that the FDA is keeping a close watch on the marketplace and will hold companies accountable for breaking the law,” said Zeller.

  • Discretion Advised

    Discretion Advised

    Mitch Zeller
    Mitch Zeller speaking at a TMA annual meeting. Photo: Taco Tuinstra
    During this year’s TMA conference, Mitch Zeller, director of the FDA’s CTP, gave his first speech since Scott Gottlieb resigned as FDA commissioner.

    It’s business as usual. Mitch Zeller, director of the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP), said the agency continues to be “in a position of transition and change” after the abrupt resignation of Scott Gottlieb as the regulatory agency’s commissioner on April 5. “There is some uncertainty,” Zeller said. “But the public health mission of the center does not change.” It was Zeller’s first major public appearance since Gottlieb stepped down.

    Speaking to a crowd of more than 130 participants during TMA’s 104th Annual Meeting and Conference, which was held in Falls Church, Virginia, USA, on April 12, Zeller discussed the FDA’s recent reports on a “possible” link between e-cigarettes and seizures. “We don’t yet have causality in these cases, but we have the reports …. We are seeing somewhat of an uptick in reporting … and a seizure is a serious incident,” Zeller said. “In fact, many of the reports we received are incomplete …. We wanted to get the word out to the public but also to those who would be in a position to do a better job of reporting in a more complete way to us.” Zeller then added that within 24 hours of making the announcement, “we have had a whole bunch of additional reports” filed with the agency.

    There have been no studies or confirmed reports of any vapor products being the primary cause of a seizure.

    Zeller also discussed the FDA’s newly proposed guidance of electronic nicotine-delivery systems (ENDS). The two main focal points surrounding the guidance are flavored e-liquids and pod systems. “The obvious concern, the 800-pound gorilla, is not just Juul, but all Juul-like products—the pod based products, that through some combination of the nicotine levels, the presence of nicotine salts, the flavors and the ease of which these products can be used so discreetly by kids,” Zeller stated. “We remarkably have some kids walking around inaccurately believing there is no nicotine in these products.”

    The FDA has stated that if pod systems remain an issue in youth vaping, the products could be removed from the market. Zeller said the FDA has the authority to pull any vapor product from the market because there were no vapor products commercially marketed in the United States as of the predicate date, Feb. 15, 2007.

    When asked how the FDA would define a pod-based system, Zeller replied, “It’s a fair question that I’m not going to answer …. The reality is there are no grandfathered ENDS products … there are no ENDS products that have received a marketing authorization through the substantial equivalency [SE] pathway,” said Zeller. “As a technical legal matter, none of these products are lawfully on the market.”

    Regarding e-liquid flavors, Zeller said that the FDA looked at all the patterns of use, and, “after taking a tremendous amount of heat from the tobacco control community,” the FDA decided to draw the line at mint, menthol and tobacco flavors. “There’s [mint-, menthol-, tobacco- and non-flavored ENDS], and then there’s everything else, whether it’s grape, strawberry, bubblegum, cotton candy, unicorn puke …. There is a difference because of how popular mint and menthol ENDS products are with adults,” said Zeller. “But because the fruit and candy flavors are so much more popular with kids, not that they aren’t popular with adults, but that is the public health balancing act that we tried to do.”

    Vapor products are on the market through an exercise in what the FDA calls “enforcement discretion,” according to Zeller. “That policy has been revisited and revised, which is our right under the law. So, for these other flavored ENDS products (excluding mint, menthol and tobacco) … those products can continue to be sold under our draft guidance,” he said. “But whether it’s in a brick-and-mortar establishment or online, there has to be some form of heightened age restriction that can prevent kids from getting access.”

    The FDA has undertaken more than 1 million compliance checks since 2010, according to Zeller. He added that the 17 companies that were recently given warning letters concerning e-liquids that could be seen as being marketed toward youth had all “completely reformed.” Issues persist, however, Zeller said. “We had to send these warning letters [recently to a company] because of the resemblance between [their] e-liquid and a heavy duty, codeine-laced prescription drug, and the concern here was ingestion … because of the resemblance … you see the deliberate resemblance in the labeling,” he said.

    During the question and answer session of his speech, Zeller was often forced to say, “I can’t comment on that right now.” When one attendee asked about the recent postponement of harmful and potentially harmful constituent testing, Zeller said, “I think I’m going to need to continue to disappoint you. We are working on it, and I can’t say anything more than that, other than we are now on record … saying that whatever the reporting requirements will be, it won’t be until after there is a final draft guidance …. Let’s just say [that] when it comes to clearance, we don’t control our own destiny … when it comes to getting things through the process.”

    Bonnie Herzog, managing director of Wells Fargo Securities, wrote in an email that Zeller was understandably “careful to refrain from making any comments” regarding most of the policies the FDA has proposed in its recent rules. “However, to us, the important nuance was what director Zeller didn’t say. Namely, he refrained from repeating former commissioner Gottlieb’s strong threats to take more decisive action on youth e-cig access (e.g., removal of e-vapor pods from the market),” said Herzog. “This nuance suggests a distancing from Gottlieb’s more severe approach in anticipation, we think, of a potentially different tone from the new acting FDA commissioner …. In sum, the conference illuminated the complexity of the issues before the FDA …. It is clearly a delicate balancing act that remains elusive.”